Drug Research
CytoviaTherapeutics and the University of California enter into a partnership to develop precision gene-edited CAR-NK celltherapy
CytoviaTherapeutics,a biopharmaceutical company, and the University of California,San Francisco(UCSF) announced that they have entered a 3-year research partnership to develop novel precision gene editing to...
Drug Research
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to...
Drug Research
BI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac Meets Primary and Secondary Endpoints
VBI Vaccines Inc. (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported top-line data from CONSTANT, the second pivotal Phase 3...
Drug Research
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing. Proceeds will be used...
Drug Research
Bayer and Exscientia collaborate to leverage the potential of AI in cardiovascular and oncology drug discovery
Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early...
Drug Research
Development of First-In-Class Antibody Therapeutics and New Acquisition Brings Hope to Patients with Fibrotic and Inflammatory Diseases
The breakthrough discovery of investigational therapies for multiple human diseases by a team of Singapore clinicians, clinician scientists and scientists from National Heart Centre Singapore...
Drug Research
Velabs Therapeutics Receives Exclusive Licence from Alytas Therapeutics for the Development of Therapeutic Antibodies as Senolytics
Velabs Therapeutics GmbH, a biotech company focused on the rapid screening of functional therapeutic antibodies announced that it has entered into an exclusive licence agreement...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.